CTI BioPharma (CTIC) Shares are Down -2.25%

CTI BioPharma (CTIC) : During the past 4 weeks, traders have been relatively bearish on CTI BioPharma (CTIC), hence the stock is down -7.54% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.3% relative to the S&P 500. The 4-week change in the price of the stock is -6.58% and the stock has fallen -2.25% in the past 1 week.

The stock has recorded a 20-day Moving Average of 0.79% and the 50-Day Moving Average is 6.97%. CTI BioPharma (NASDAQ:CTIC): stock turned positive on Friday. Though the stock opened at $0.3461, the bulls momentum made the stock top out at $0.3588 level for the day. The stock recorded a low of $0.3432 and closed the trading day at $0.3476, in the green by 3.15%. The total traded volume for the day was 1,076,776. The stock had closed at $0.337 in the previous days trading.


The company Insiders own 3.01% of CTI BioPharma shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -1.11% . Institutional Investors own 38.29% of CTI BioPharma shares. During last six month period, the net percent change held by insiders has seen a change of -13.45%.

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *